Aim: To evaluate how efficacy outcomes from real-world data (RWD) can support those from randomized controlled trials (RCTs), in the context of first-line tyrosine kinase inhibitor treatment of metastatic renal cell carcinoma. Patients & methods: PubMed, Ovid, MEDLINE and EMBASE were searched for RCTs and RWD studies with ≥50 adult patients per arm published in 2000-2017. Outcome measures were median progression-free survival, median overall survival and objective response rate. Results: A total of 13 RCTs and 22 RWD studies met eligibility criteria; 31, 28 and 25 studies, respectively, reported median progression-free survival, median overall survival and objective response rate. Summary outcome measures were similar in RWD and RCTs. Conclusion: RWD validates efficacy-based outcomes from RCTs and may provide supportive evidence to inform clinical decisions.
CITATION STYLE
Moran, M., Nickens, D., Adcock, K., Bennetts, M., Charnley, N., & Fife, K. (2019). Augmenting the randomized controlled trial with real-world data to aid clinical decision making in metastatic renal cell carcinoma: A systematic review and meta-analysis. Future Oncology. Future Medicine Ltd. https://doi.org/10.2217/fon-2019-0421
Mendeley helps you to discover research relevant for your work.